Literature DB >> 22899381

Development and evaluation of an in vitro vaginal model for assessment of drug's biopharmaceutical properties: curcumin.

Katja Berginc1, Nataša Skalko-Basnet, Purusotam Basnet, Albin Kristl.   

Abstract

Vaginal administration is a promising alternative to the per-oral route in achieving systemic or local therapeutic effects, when intestinal drug absorption is hindered by problematic biopharmaceutical drug properties. The aim of this study was to establish an in vitro vaginal model and use it to characterize biopharmaceutical properties of liposomally associated curcumin destined for vaginal delivery. The in vitro permeability, metabolism, and tissue retention of high/low permeable compounds were assessed on cow vaginal mucosa and compared to the permeabilities determined through Caco-2 cells and rat jejunum in vitro. The results showed that the intestinal mucosa was superior to the vaginal one in categorizing drugs based on their permeabilities in high/low permeable classes. Passive diffusion was found to be the main mechanism of drug penetration through vaginal mucosa and it was not affected by transporter-enzyme alliance, as their expression/activity was significantly reduced compared to the intestinal tract. Curcumin permeability from the solution form was the lowest of all tested substances due to its significant tissue retention and curcumin-mucus interactions. The permeability of liposomally associated curcumin was even lower but the binding of liposomally associated curcumin to the vaginal tissue was significantly higher. The permeability and tissue retention of liposomal curcumin were vesicle size dependent. Vaginal application of liposomally associated curcumin provides relatively high levels of curcumin in vaginal tissue, with limited systemic absorption.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22899381      PMCID: PMC3513450          DOI: 10.1208/s12249-012-9837-9

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  37 in total

Review 1.  Ultrastructural and rheological properties of bovine vaginal fluid and its relation to sperm motility and fertilization: a review.

Authors:  J Rutllant; M López-Béjar; F López-Gatius
Journal:  Reprod Domest Anim       Date:  2005-04       Impact factor: 2.005

2.  Intestinal absorptive transport of the hydrophilic cation ranitidine: a kinetic modeling approach to elucidate the role of uptake and efflux transporters and paracellular vs. transcellular transport in Caco-2 cells.

Authors:  David L Bourdet; Gary M Pollack; Dhiren R Thakker
Journal:  Pharm Res       Date:  2006-06-08       Impact factor: 4.200

3.  Bovine trichomoniasis as a model for development of vaccines against sexually-transmitted disease.

Authors:  L B Corbeil; L Munson; C Campero; R H BonDurant
Journal:  Am J Reprod Immunol       Date:  2001-05       Impact factor: 3.886

4.  Performance of an in vitro mucoadhesion testing method for vaginal semisolids: influence of different testing conditions and instrumental parameters.

Authors:  José das Neves; Maria Helena Amaral; Maria Fernanda Bahia
Journal:  Eur J Pharm Biopharm       Date:  2008-01-14       Impact factor: 5.571

5.  Microencapsulation of self-microemulsifying system: improving solubility and permeability of furosemide.

Authors:  A Zvonar; K Berginc; A Kristl; M Gasperlin
Journal:  Int J Pharm       Date:  2010-01-07       Impact factor: 5.875

6.  Chemical changes in cervical mucus from normal and ovariectomized cows treated with hormones.

Authors:  D R Lamond; A G Shanahan
Journal:  Biol Reprod       Date:  1969-12       Impact factor: 4.285

7.  The absorption of beta-adrenoceptor antagonists in rat in-situ small intestine; the effect of lipophilicity.

Authors:  D C Taylor; R Pownall; W Burke
Journal:  J Pharm Pharmacol       Date:  1985-04       Impact factor: 3.765

8.  Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells.

Authors:  M Takano; R Hasegawa; T Fukuda; R Yumoto; J Nagai; T Murakami
Journal:  Eur J Pharmacol       Date:  1998-10-09       Impact factor: 4.432

9.  Development of controlled release sildenafil formulations for vaginal administration.

Authors:  I Tuncer Değim; Fatmanur Tuğcu-Demiröz; Sibel Tamer-Ilbasmis; Füsun Acartürk
Journal:  Drug Deliv       Date:  2008-05       Impact factor: 6.419

10.  Structural studies on the glycoproteins from bovine cervical mucus.

Authors:  G P Roberts
Journal:  Biochem J       Date:  1978-09-01       Impact factor: 3.857

View more
  6 in total

1.  In vitro efficacy of curcumin on Trichomonas vaginalis.

Authors:  Benjamin Wachter; Michael Syrowatka; Andreas Obwaller; Julia Walochnik
Journal:  Wien Klin Wochenschr       Date:  2014-03-12       Impact factor: 1.704

2.  Development and characterization of polymer-coated liposomes for vaginal delivery of sildenafil citrate.

Authors:  Hanan Refai; Doaa Hassan; Rehab Abdelmonem
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

3.  The anti-inflammatory activity of curcumin protects the genital mucosal epithelial barrier from disruption and blocks replication of HIV-1 and HSV-2.

Authors:  Victor H Ferreira; Aisha Nazli; Sara E Dizzell; Kristen Mueller; Charu Kaushic
Journal:  PLoS One       Date:  2015-04-09       Impact factor: 3.240

4.  Localized Therapy of Vaginal Infections and Inflammation: Liposomes-In-Hydrogel Delivery System for Polyphenols.

Authors:  May Wenche Jøraholmen; Purusotam Basnet; Mia Jonine Tostrup; Sabrin Moueffaq; Nataša Škalko-Basnet
Journal:  Pharmaceutics       Date:  2019-01-27       Impact factor: 6.321

5.  Development of a Novel Vaginal Drug Delivery System to Control Time of Farrowing and Allow Supervision of Piglet Delivery.

Authors:  Sophia A Ward; Roy N Kirkwood; Kate J Plush; Sadikalmahdi Abdella; Yunmei Song; Sanjay Garg
Journal:  Pharmaceutics       Date:  2022-01-31       Impact factor: 6.321

6.  Bioadhesive mini-tablets for vaginal drug delivery.

Authors:  Marianne Hiorth; Susanne Nilsen; Ingunn Tho
Journal:  Pharmaceutics       Date:  2014-08-27       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.